Skip to content

Advertisement

Open Peer Review Reports for: The antifibrotic drug pirfenidone inhibits spondyloarthritis fibroblast-like synoviocytes and osteoblasts in vitro

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
22 May 2018 Submitted Original manuscript
27 Jul 2018 Reviewed Reviewer Report - Angelo Calado
1 Aug 2018 Reviewed Reviewer Report - Leyre Brizuela
8 Aug 2018 Author responded Author comments - Julie Stougaard
Resubmission - Version 2
8 Aug 2018 Submitted Manuscript version 2
14 Aug 2018 Author responded Author comments - Julie Stougaard
Resubmission - Version 3
14 Aug 2018 Submitted Manuscript version 3
26 Aug 2018 Author responded Author comments - Julie Stougaard
Resubmission - Version 4
26 Aug 2018 Submitted Manuscript version 4
4 Sep 2018 Author responded Author comments - Julie Stougaard
Resubmission - Version 5
4 Sep 2018 Submitted Manuscript version 5
5 Sep 2018 Author responded Author comments - Julie Stougaard
Resubmission - Version 6
5 Sep 2018 Submitted Manuscript version 6
5 Sep 2018 Author responded Author comments - Julie Stougaard
Resubmission - Version 7
5 Sep 2018 Submitted Manuscript version 7
11 Sep 2018 Author responded Author comments - Julie Stougaard
Resubmission - Version 8
11 Sep 2018 Submitted Manuscript version 8
18 Sep 2018 Author responded Author comments - Julie Stougaard
Resubmission - Version 9
18 Sep 2018 Submitted Manuscript version 9
Publishing
14 Oct 2018 Editorially accepted
19 Nov 2018 Article published 10.1186/s41927-018-0040-9

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement